IXHL

IXHL

USD

Incannex Healthcare Inc. Common Stock

$0.339-0.005 (-1.480%)

リアルタイム価格

Healthcare
Drug Manufacturers - Specialty & Generic
オーストラリア

価格チャート

Loading Chart...

主要指標

市場指標
企業ファンダメンタルズ
取引統計

市場指標

始値

$0.344

高値

$0.349

安値

$0.336

出来高

15.84M

企業ファンダメンタルズ

時価総額

118.0M

業種

Drug Manufacturers - Specialty & Generic

Australia

取引統計

平均出来高

66.44M

取引所

NCM

通貨

USD

52週レンジ

安値 $0.08現在値 $0.339高値 $3.12

関連ニュース

GlobeNewswire

Incannex Reports Positive Results from Phase 2 Clinical Trial of PSX-001 (Psi-GAD) for Generalised Anxiety Disorder

MELBOURNE, Australia and NEW YORK, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL) ("Incannex" or the "Company") is pleased to report positive data from its Phase 2 clinical trial of PSX-001

もっと見る
Incannex Reports Positive Results from Phase 2 Clinical Trial of PSX-001 (Psi-GAD) for Generalised Anxiety Disorder
GlobeNewswire

Incannex Healthcare Authorizes $20 Million Share Repurchase Program

MELBOURNE, Australia and NEW YORK, Aug. 22, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL) ("Incannex" or the "Company"), a clinical-stage biopharmaceutical company developing innovative combination

もっと見る
Incannex Healthcare Authorizes $20 Million Share Repurchase Program
GlobeNewswire

Incannex Receives Positive Patient-Reported Outcomes and Compelling Phase 2 Efficacy Data for IHL-42X in Obstructive Sleep Apnoea

MELBOURNE, Australia and NEW YORK, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL), a clinical-stage pharmaceutical company developing innovative combination therapies for prevalent medical

もっと見る
Incannex Receives Positive Patient-Reported Outcomes and Compelling Phase 2 Efficacy Data for IHL-42X in Obstructive Sleep Apnoea